Purwar Shashank, Gupta Shipra, John Julie Hansa, Gupta Priyal, Halder Ajay
Department of Microbiology, All India Institute of Medical Sciences, Bhopal, Madhya Pradesh, India.
Department of Obstetrics and Gynaecology, All India Institute of Medical Sciences, Bhopal, Madhya Pradesh, India.
J Midlife Health. 2023 Jan-Mar;14(1):8-14. doi: 10.4103/jmh.jmh_251_22. Epub 2023 Jul 7.
The objective of our study was to assess whether urinary samples for human papilloma virus (HPV) detection are a good predictive marker of cervical cancerous and precancerous lesions, by comparing against results from cervical scrapings as the gold standard test.
The study is a hospital-based cross-sectional study wherein symptomatic women were screened at the colposcopy clinic. Paired samples-cervical scrapings/washings and urine samples were tested for hr-HPV for women who were found to harbor premalignant and malignant lesions of the cervix in histopathological lesions, by multiplex real-time polymerase chain reaction and HPV genotyping. Diagnostic accuracy was tested by calculating concordance with Cohen's kappa with hr-HPV detection in cervical samples as the gold standard.
A total of 295 patients undergoing colposcopy were recruited in the study, out of which 54 had histopathological-proven premalignant and malignant lesions of the cervix. Overall, positivity rate in urinary samples for both HPV 16 and 18 combined is 64.81%, whereas for cervical samples is 68.51%. HPV 16 was seen in 30 (55.5%) and 32 (59.3%) cervical and urinary samples, respectively, whereas HPV 18 was seen in 7 (12.9%) and 6 (11.1%) samples, respectively. There was substantial concordance between the cervical samples and first-void urinary samples results with Cohen's k: 0.6988 (95% confidence interval: From 0.507 to 0.891). There was 85.96% agreement among all the tests that were performed with only 14.04% disagreement.
The study showed that HPV DNA detection from the urine and cervical samples showed significant agreeability for the detection of precancerous and cancerous lesions of the cervix among women with abnormal histology results. Thus, urinary sampling can be done as a potential replacement for cervical sampling methods with the added benefit as it can be used in females reluctant to provide cervical samples, if there is no availability of skilled workforce for collecting samples, for mass screening, and for the follow-up of vaccination programs.
我们研究的目的是通过与作为金标准检测的宫颈刮片结果进行比较,评估用于检测人乳头瘤病毒(HPV)的尿液样本是否是宫颈癌前病变和癌性病变的良好预测指标。
本研究是一项基于医院的横断面研究,对阴道镜门诊中有症状的女性进行筛查。对于组织病理学检查发现患有宫颈恶性前病变和恶性病变的女性,通过多重实时聚合酶链反应和HPV基因分型,对配对样本(宫颈刮片/冲洗液和尿液样本)进行高危型HPV检测。以宫颈样本中hr-HPV检测结果作为金标准,通过计算与科恩kappa系数的一致性来检验诊断准确性。
本研究共招募了295例接受阴道镜检查的患者,其中54例经组织病理学证实患有宫颈恶性前病变和恶性病变。总体而言,HPV 16和18联合检测的尿液样本阳性率为64.81%,而宫颈样本阳性率为68.51%。HPV 16分别在30例(55.5%)宫颈样本和32例(59.3%)尿液样本中检出,而HPV 18分别在7例(12.9%)宫颈样本和6例(11.1%)尿液样本中检出。宫颈样本和首次晨尿样本结果之间存在高度一致性,科恩kappa系数为0.6988(95%置信区间:0.507至0.891)。所有检测结果的一致性为85.96%,不一致性仅为14.04%。
该研究表明,对于组织学结果异常的女性,从尿液和宫颈样本中检测HPV DNA在检测宫颈前癌和癌性病变方面显示出显著的一致性。因此,尿液采样可作为宫颈采样方法的潜在替代方法,其额外优势在于,在缺乏熟练样本采集人员、用于大规模筛查以及疫苗接种项目随访时,可用于不愿提供宫颈样本的女性。